

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 300.1023		SERIAL NO.: 09/726,193	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): CHEN et al.			
				FILING DATE: November 29, 2000		GROUP: 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BF	AC	Approval letter from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 000, October 13, 2000					
	AD	Approved Label for Glucophage/Glucophage XR, NDA 21-202, Supplement 000, October 13, 2000					
	AE	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 003, January 8, 2002					
	AF	Approval letter on formulation revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 008, April 11, 2003					
	AG	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 011, March 19, 2004					
	AH	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 013, March 19, 2004					
	AI	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 001, April 19, 2001					
	AJ	Approved Label For Glucophage/Glucophage XR NDA 21-202, Supplement 013, March 19, 2004					
	AK	Approved Label for Glucophage/Glucophage XR NDA 21-202, Supplement 011, March 19, 2004					
BF	AL	Approved Label for Glucophage/Glucophage XR NDA 21-201, Supplement 008, labeling revision, April 11, 2003					
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
EXAMINER /Blessing Fubara/				DATE CONSIDERED 06/25/2006			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 300.1023		SERIAL NO.: 09/726,193	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): CHEN et al.			
				FILING DATE: November 29, 2000		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
BF	BA 6 1 1 7 4 5 1	09/12/00	Kumar	424	465		
	BB 6 8 6 6 8 6 6	03/15/05	Chen et al.	424	468		
	BC 6 7 9 0 4 5 9	09/14/04	Cheng et al.	424	468		
	BD 5 9 2 2 7 6 9	07/13/99	Barelli et al.	514	616		
	BE 6 0 5 1 5 9 7	04/18/00	Zhang et al.	514	414		
	BF 6 0 1 1 0 4 9	01/04/00	Whitcomb	514	369		
	BG 6 1 9 1 1 6 2	02/20/01	Byrd et al.	514	440		
	BH 20 04 02 19 2 0 9	11/04/04	Chen et al.				
	BI 20 06 00 34 9 2 2	02/16/06	Cheng et al.				
	BJ 20 06 00 08 5 2 5	01/12/06	Chen et al.				
	BK 20 06 00 08 5 2 4	01/12/06	Chen et al.				
	BL 20 06 00 08 5 2 3	01/12/06	Chen et al.				
	BM 20 06 00 08 5 2 6	01/12/06	Chen et al.				
BF	BN 20 04 00 52 8 4 8	03/18/04	Cheng et al.				
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					YES	NO	
BF BO 2 2 5 1 4 3 0	02/28/00	CA	A61K	31/44			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BF	BP	E.K. Kastrup: "Anidiabetic Agents," DRUG FACTS AND COMPARISONS, 1999, St. Louis, pp 635-642					
BF	BQ	Andrx Pilot Biostudy Data (20 pages)					
BF	BR	Chiao, C. Sustained-Release Drug Delivery Systems; Remington: the Science and Practice of Pharmacy, 1995, Mack Publishing Company, Easton PA pgs. 1660-1669					
BF	BS	Drug Facts and Comparisons pages 130n-130u (1999)					
EXAMINER /Blessing Pubara/				DATE CONSIDERED 06/25/2006			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							